What is the recommended treatment for Yersinia enterocolitica infection?

Treatment of Yersinia enterocolitica Infection

For uncomplicated Yersinia enterocolitica gastroenteritis in immunocompetent patients, antibiotic therapy is not routinely recommended as the infection is typically self-limiting 1, 2. However, specific patient populations and severe presentations require antimicrobial intervention.

When to Treat with Antibiotics

Antibiotic therapy is indicated for:

• Severely ill or immunocompromised patients (including those with malignancy, HIV, or receiving immunosuppressive therapy) 1
• Bacteremia or septicemia (mortality can reach 50% without treatment) 2, 3
• Invasive extraintestinal infections (septic arthritis, osteomyelitis, hepatic/splenic abscesses) 4
• Infants younger than 3 months (at increased risk for bacteremia) 3
• Patients with iron overload or receiving desferrioxamine therapy 5
• Patients with underlying conditions such as sickle cell disease 3

First-Line Antibiotic Regimens

For Severe Disease or Invasive Infection

The preferred regimen is a third-generation cephalosporin combined with gentamicin 1:

• Ceftriaxone 1-2 g IV every 12-24 hours (adults) or appropriate pediatric dosing PLUS
• Gentamicin 5-7 mg/kg IV every 24 hours 1, 3

Alternative monotherapy options for severe disease:

• Fluoroquinolones (ciprofloxacin 400 mg IV every 12 hours or 500-750 mg PO every 12 hours) are highly effective and should be considered first-line therapy for invasive infections 1, 2, 4
• Cefotaxime (1-2 g IV every 6-8 hours in adults; highly effective for bacteremia in children) 3

For Moderate Disease in Immunocompromised Hosts

Oral fluoroquinolone monotherapy (ciprofloxacin) is appropriate for less severe presentations requiring treatment 1, 4.

Alternative oral option:

• Trimethoprim-sulfamethoxazole (5 mg/kg of trimethoprim component every 8 hours) 1, 3
• Doxycycline 1

Treatment Duration

• Standard enterocolitis requiring treatment: 7-10 days 1
• Bacteremia/septicemia: 10-14 days minimum 2
• Invasive skeletal infections: Extended therapy (ciprofloxacin was used successfully for weeks in documented cases) 4

Antimicrobial Susceptibility Profile

Y. enterocolitica demonstrates consistent susceptibility to:

• Third-generation cephalosporins (cefotaxime 99%, ceftazidime 89%) 3
• Aminoglycosides (gentamicin, tobramycin 100%) 3
• Fluoroquinolones 2, 4
• Trimethoprim-sulfamethoxazole (100%) 3

All isolates are resistant to:

• First-generation cephalosporins 3
• Ampicillin and amoxicillin (intrinsic β-lactamase production) 2

Critical Clinical Pitfalls

Do not treat uncomplicated gastroenteritis in healthy children and adults - studies show no clinical benefit from oral antibiotics (including trimethoprim-sulfamethoxazole) compared to supportive care alone 3. This unnecessarily exposes patients to antibiotic side effects and promotes resistance.

Obtain blood cultures in high-risk patients before dismissing symptoms as simple gastroenteritis, particularly in infants <3 months, patients with sickle cell disease, those with iron overload, and immunocompromised individuals 3, 5.

Consider surgical intervention for complications such as intestinal necrosis, which may develop in severe cases 6.

Special Population: Pregnant Women

While the available guidelines focus on plague rather than yersiniosis, the general principles for gram-negative infections suggest fluoroquinolones or third-generation cephalosporins remain reasonable options when treatment is necessary, with gentamicin preferred over other aminoglycosides due to lower fetal toxicity risk 1.

Epidemiologic Context

Y. enterocolitica accounts for a significant proportion of bacterial gastroenteritis (12.6% in one pediatric series), with peak incidence during winter months (November-January) 3. Exposure to raw pork products (particularly chitterlings) is a major risk factor, especially for infants 3, 5.